• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by CureVac N.V.

    3/27/25 4:30:33 PM ET
    $CVAC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CVAC alert in real time by email
    6-K 1 tm2510706d1_6k.htm FORM 6-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    For the month of March 2025

     

     

     

    Commission File Number: 001-39446

     

    CureVac N.V.

    (Exact Name of Registrant as Specified in Its Charter)

     

    Friedrich-Miescher-Strasse 15, 72076

    Tübingen, Germany

    +49 7071 9883 0

    (Address of principal executive office)

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

     

    Form 20-F x    Form 40-F ¨ 

     

     

     

     

     

     

    On March 27, 2025, CureVac N.V. (the “Company”) issued a press release announcing the decision of the European Patent Office in a patent litigation with BioNTech SE.

     

    The information included in this Form 6-K (including Exhibit 99.1, but excluding the statements of the Company’s Chief Executive Officer contained in Exhibit 99.1 hereto) is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-259613).

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      CUREVAC N.V.
         
      By:   /s/ Alexander Zehnder  
        Chief Executive Officer

     

    Date: March 27, 2025

     

     

     

     

    EXHIBIT INDEX

     

    EXHIBIT NO.   DESCRIPTION
    99.1   CureVac N.V. Press Release dated March 27, 2025.

     

     

     

    Get the next $CVAC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CVAC

    DatePrice TargetRatingAnalyst
    4/25/2024$12.00 → $4.00Outperform → Market Perform
    Leerink Partners
    6/8/2023$13.00Outperform
    SVB Securities
    1/19/2023$8.00 → $18.00Neutral → Buy
    UBS
    1/9/2023$9.00 → $21.00Hold → Buy
    Jefferies
    1/21/2022$55.00 → $20.00Neutral → Underperform
    B of A Securities
    1/18/2022$52.00Market Outperform
    JMP Securities
    10/22/2021$35.00Hold
    Deutsche Bank
    More analyst ratings

    $CVAC
    Leadership Updates

    Live Leadership Updates

    See more
    • CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

      Experienced CFO and investment banker with 30-year track record will help drive CureVac's transformationTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the appointment of Axel Sven Malkomes as Chief Financial Officer, effective November 11, 2024.Mr. Malkomes joins CureVac at a pivotal moment as the company enters a new chapter of growth and innovation, bringing over three decades of senior corporate and investment banking experience within the biotech and pharmaceutical industries."Axel's

      11/4/24 7:20:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer

      Agomab Therapeutics NV (‘Agomab') today announced that Pierre Kemula will join the company as Chief Financial Officer (CFO) effective November 1, 2024, bringing more than 15 years of experience in global biotech financial leadership. Mr. Kemula joins Agomab from CureVac N.V. (NASDAQ:CVAC), where he currently serves as CFO. In this role, Mr. Kemula has led CureVac's financial and capital markets activities since 2016, characterized by a successful listing on Nasdaq and two subsequent follow-on offerings. Under his leadership, CureVac raised over $1.6 billion in equity. Mr. Kemula will succeed Tolga Hassan, who has recently left the company to explore new opportunities closer to home. Follo

      7/11/24 7:00:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac Announces Voting Results of General Meeting

      TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 24, 2024 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the voting results of the Company's annual general meeting.The shareholders of the Company voted in favor of all proposals. These proposals included the appointment of Thaminda Ramanayake and the reappointment of Malte Greune as members of the Management Board, both effective June 24th, 2024. Additionally, Jean Stéphenne and Mathias Hothum were reappointed as members of the supervisory board, Birgit Hofmann was appointed as a new member of t

      6/24/24 4:20:00 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVAC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CureVac downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded CureVac from Outperform to Market Perform and set a new price target of $4.00 from $12.00 previously

      4/25/24 7:53:11 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Securities initiated coverage on CureVac with a new price target

      SVB Securities initiated coverage of CureVac with a rating of Outperform and set a new price target of $13.00

      6/8/23 7:45:44 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac upgraded by UBS with a new price target

      UBS upgraded CureVac from Neutral to Buy and set a new price target of $18.00 from $8.00 previously

      1/19/23 7:20:10 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVAC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

      Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter€400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to €551 million; expected cash runway re-affirmed into 2028CVGBM Phase 1 glioblastoma study showed 77% of patients with antigen-specific T-cell responses; data presented at ESMO, SITC and SNONew off-the-shelf program for squamous non-small cell lung cancer started, expected to enter Phase 1 in H2 2025New preclinical prophylactic vaccine program for urinary tract infections initiated, supported by positive preclinical data versus protein-based vaccinesPositive Phase 2 data from seasonal influen

      11/12/24 7:20:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

      TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the third quarter and first nine months 2024 on Tuesday, November 12, 2024. The company will host a conference call and webcast on the same day at3 p.m. CET / 9 a.m. EST.Dial-in numbers to participate in the conference call:U.S. Toll-Free: +1-877-407-0989International: +1-201-389-0921Germany: 0800-182-0040 (landline access) / 0800-184-4713 (cell phone access)The live webcast link can be accesse

      11/7/24 7:30:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

      Experienced CFO and investment banker with 30-year track record will help drive CureVac's transformationTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the appointment of Axel Sven Malkomes as Chief Financial Officer, effective November 11, 2024.Mr. Malkomes joins CureVac at a pivotal moment as the company enters a new chapter of growth and innovation, bringing over three decades of senior corporate and investment banking experience within the biotech and pharmaceutical industries."Axel's

      11/4/24 7:20:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by CureVac N.V. (Amendment)

      SC 13G/A - CureVac N.V. (0001809122) (Subject)

      2/14/24 5:01:40 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by CureVac N.V. (Amendment)

      SC 13G/A - CureVac N.V. (0001809122) (Subject)

      2/6/24 5:10:10 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by CureVac N.V.

      SC 13G - CureVac N.V. (0001809122) (Subject)

      3/27/23 5:00:14 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVAC
    Financials

    Live finance-specific insights

    See more
    • CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

      Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter€400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to €551 million; expected cash runway re-affirmed into 2028CVGBM Phase 1 glioblastoma study showed 77% of patients with antigen-specific T-cell responses; data presented at ESMO, SITC and SNONew off-the-shelf program for squamous non-small cell lung cancer started, expected to enter Phase 1 in H2 2025New preclinical prophylactic vaccine program for urinary tract infections initiated, supported by positive preclinical data versus protein-based vaccinesPositive Phase 2 data from seasonal influen

      11/12/24 7:20:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

      TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the third quarter and first nine months 2024 on Tuesday, November 12, 2024. The company will host a conference call and webcast on the same day at3 p.m. CET / 9 a.m. EST.Dial-in numbers to participate in the conference call:U.S. Toll-Free: +1-877-407-0989International: +1-201-389-0921Germany: 0800-182-0040 (landline access) / 0800-184-4713 (cell phone access)The live webcast link can be accesse

      11/7/24 7:30:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update

      Closed new licensing agreement with GSK worth up to €1.45 billion, including €400 million upfront; provides strong validation of CureVac's mRNA platformInitiated strategic workforce reduction of ~30% by end of 2024, optimizing business to focus on high-value opportunities in oncology, infectious diseases and other areasInvoiced €10 million milestone payment after Phase 2 transition of pre-pandemic avian influenza (H5N1) program; candidate fully licensed to GSK under new agreementDosing of first patient in Phase 1 study Part B in glioblastoma with CVGBM to establish dose-confirmation; initial dose-escalation Part A data accepted for oral presentation at ESMOStrengthening of Supervisory Board

      8/15/24 7:30:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVAC
    SEC Filings

    See more
    • SEC Form 20-F filed by CureVac N.V.

      20-F - CureVac N.V. (0001809122) (Filer)

      4/10/25 5:58:45 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by CureVac N.V.

      6-K - CureVac N.V. (0001809122) (Filer)

      4/10/25 4:01:49 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by CureVac N.V.

      6-K - CureVac N.V. (0001809122) (Filer)

      4/7/25 4:01:39 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care